Synergy Pharmaceuticals Initiates First Phase 3 Clinical Trial Of Plecanatide In Patients With Chronic Idiopathic Constipation
Published: Nov 13, 2013
NEW YORK--(BUSINESS WIRE)--Synergy Pharmaceuticals Inc. (NASDAQ:SGYP) today announced the start of the first of two planned phase 3 clinical trials to confirm the safety and efficacy of plecanatide, its lead GC-C agonist and once-daily oral treatment, in adult patients with chronic idiopathic constipation (CIC).
Help employers find you! Check out all the jobs and post your resume.